STOCK TITAN

Pasqal Holding SA 424B Filings

PSQL NASDAQ

Every 424B that Pasqal Holding SA (PSQL) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 424B covers the supplement that carries the terms of a priced offering, so if you follow PSQL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PSQL filings page.

Rhea-AI Summary

Pasqal Holding SA (PSQL) registered up to 17,333,333 Ordinary Shares for issuance upon exercise of Public and Private Placement Warrants, and up to 286,674,886 Ordinary Shares plus 7,750,000 Private Placement Warrants for resale by selling securityholders.

The issuance shares comprise 9,583,333 Public Warrant shares and 7,750,000 Private Placement Warrant shares, exercisable at $11.50 per Ordinary Share, subject to adjustment. Resale shares include up to 56,287,179 shares issuable upon Convertible Bond conversion, assuming a $7.80 conversion price and payment-in-kind interest accrued for three years from the Closing Date, and up to 50,080,128 shares issuable upon Investment Warrant exercise, assuming a $7.80 exercise price. Pasqal receives proceeds from cash exercises of Warrants and Investment Warrants, but not from securityholder resales or resale of the underlying shares.

Pasqal reported revenue of €16.4 million for the year ended December 31, 2025, and €4.9 million for the six months ended June 30, 2026. Net losses were €92.4 million in 2025 and €48.5 million in 2024.

Rhea-AI Summary

Pasqal Holding SA's prospectus supplement covers issuance of up to 17,333,333 ordinary shares upon warrant exercise and selling-securityholder resales of up to 286,674,886 ordinary shares and 7,750,000 Private Placement Warrants. Each Warrant is exercisable at $11.50 per ordinary share, subject to adjustment; Pasqal receives proceeds from cash exercises of Warrants or Investment Warrants.

Separately, Pasqal says its collaboration with French public authorities will now focus on commercial applications. It is ending its participation in LSQUARE (PROQCIMA) after the first phase, in which it says it completed all technological objectives. Pasqal has been invited to participate in civil public-support programs being defined, and the French SGPI and DGE requested a specific research and development program for fault-tolerant quantum computing based on neutral atoms.

Rhea-AI Summary

Pasqal Holding SA (PSQL) registered up to 17,333,333 ordinary shares issuable upon warrant exercise. The prospectus also covers selling securityholders’ resale of up to 286,674,886 ordinary shares and 7,750,000 Private Placement Warrants. Each Public or Private Placement Warrant is exercisable at $11.50 per share, subject to adjustment; Pasqal receives proceeds from exercises to the extent the Warrants or Investment Warrants are exercised for cash.

For the six months ended June 30, 2026, revenue was €4.872 million, up 14% from €4.286 million; QPU-related services revenue rose 34% to €3.944 million, primarily reflecting the timing of revenue recognition for the Forschungszentrum Jülich QPU upgrade. Net loss was €53.236 million versus €26.118 million, and operating loss was €59.161 million versus €19.773 million. Cash and cash equivalents were €110.835 million at June 30, 2026. Management said that cash and proceeds from the Business Combination and March 2026 Financing would be sufficient for working capital and capital expenditure needs for the next twelve months.

Rhea-AI Summary

Pasqal Holding SA (PSQL) has filed a shelf registration covering the potential primary issuance of up to 17,333,333 Ordinary Shares upon exercise of outstanding Public and Private Placement Warrants, each exercisable at $11.50 per share, and the resale by selling securityholders of up to 286,674,886 Ordinary Shares and 7,750,000 Private Placement Warrants.

The company will receive cash only if the Warrants or Investment Warrants are exercised, with net proceeds earmarked for general corporate purposes; it will receive no proceeds from selling securityholder resales. The filing also details Pasqal’s recent SPAC Business Combination, a $312.5 million Senior Unsecured Convertible Bond financing, and its position as an emerging growth and foreign private issuer developing neutral-atom quantum computing systems.